Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2 as ChEMBL target CHEMBL5291949, mapped to UniProt P18507. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2 matters
Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2 is reviewed as Gamma-aminobutyric acid receptor subunit gamma-2 (UniProt P18507); the current evidence base includes 1 approved drug, 2 compounds, and 1 assay, with lead potency reaching pChEMBL 7.0.
Gamma-aminobutyric acid receptor subunit gamma-2 Sequence length is 475 aa.
Review this target as Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2, mapped to UniProt P18507. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit gamma-2. Sequence length is 475 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 2 compounds, and 1 assay for this target. The dominant activity type is EC50. CHEMBL1568698 is the current potency anchor at pChEMBL 7.0.
Use CHEMBL1568698 as the tractability anchor when discussing potency (pChEMBL 7.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P18507, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1568698
|
7.0 | EC50 | Approved |
|
|
No preferred name
CHEMBL5281882
|
6.7 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GANAXOLONE
CHEMBL1568698
|
2022 |